Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas

Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas Research Original Investigation RNA Oncoimmune Phenotyping of HPV-Positive Oropharyngeal Cancer by Nodal Status Invited Commentary Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas A Path to Deintensification? Arun Sharma, MD, MS Human papillomavirus (HPV)-positive oropharyngeal squa- carcinoma, genes from other pathways play a role as well and mous cell carcinoma (OPSCC) is associated with p16 should be assessed when generating a predictive gene signa- overexpression and a better prognosis than HPV-negative ture. Inclusion of additional pathways could improve the pre- OPSCC. Concurrent treatment with standard-dose radiation dictive value of the gene signature. After the gene signature therapy (RT) (66-70 Gy) and was identified in this study, ROC analysis demonstrated an im- platinum-based chemo- pressive AUC of 0.933. However, as the authors acknowl- Related article page 967 therapy is highly effective for edge, it is possible that the small sample size and lack of a vali- most patients with p16-positive OPSCC, but more than 40% dation group may have resulted in overfitting the data and of patients experience severe late toxic effects when treated overestimation of the predictive value of the gene signature. with concurrent chemoradiation therapy (CRT). The advent An ideal study would develop a gene signature http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Otolaryngology - Head & Neck Surgery American Medical Association

Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas

JAMA Otolaryngology - Head & Neck Surgery , Volume 144 (11) – Nov 18, 2018

Loading next page...
 
/lp/american-medical-association/gene-expression-profiling-in-hpv-positive-p16-positive-oropharyngeal-dj2IzD5GXD
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6181
eISSN
2168-619X
DOI
10.1001/jamaoto.2018.0774
Publisher site
See Article on Publisher Site

Abstract

Research Original Investigation RNA Oncoimmune Phenotyping of HPV-Positive Oropharyngeal Cancer by Nodal Status Invited Commentary Gene Expression Profiling in HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas A Path to Deintensification? Arun Sharma, MD, MS Human papillomavirus (HPV)-positive oropharyngeal squa- carcinoma, genes from other pathways play a role as well and mous cell carcinoma (OPSCC) is associated with p16 should be assessed when generating a predictive gene signa- overexpression and a better prognosis than HPV-negative ture. Inclusion of additional pathways could improve the pre- OPSCC. Concurrent treatment with standard-dose radiation dictive value of the gene signature. After the gene signature therapy (RT) (66-70 Gy) and was identified in this study, ROC analysis demonstrated an im- platinum-based chemo- pressive AUC of 0.933. However, as the authors acknowl- Related article page 967 therapy is highly effective for edge, it is possible that the small sample size and lack of a vali- most patients with p16-positive OPSCC, but more than 40% dation group may have resulted in overfitting the data and of patients experience severe late toxic effects when treated overestimation of the predictive value of the gene signature. with concurrent chemoradiation therapy (CRT). The advent An ideal study would develop a gene signature

Journal

JAMA Otolaryngology - Head & Neck SurgeryAmerican Medical Association

Published: Nov 18, 2018

References